StockData
GeneDx Holdings Corp. logo

GeneDx Holdings Corp. (WGS) stock

WGSNasdaqServices-Health ServicesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/3043% above fair value
$45.46−3.78 (-7.68%)

Close on Nov 20, 2026Market cap $1.36BP/E –Yield –

GeneDx net income

Net income is the profit left for shareholders after every expense, interest and tax.

GeneDx's net income for the twelve months ending Jun 30, 2026 was -$106.36M, down 7664.5% year over year. For fiscal 2025 it was -$21.02M. The highest annual figure on record is -$21.02M in fiscal 2025.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$21.02M–
FY2024Dec 31, 2024-$52.29M–
FY2023Dec 31, 2023-$175.77M–
FY2022Dec 31, 2022-$548.98M–
FY2021Dec 31, 2021-$245.39M–
FY2020Dec 31, 2020-$241.34M–
FY2019Dec 31, 2019-$29.70M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$17.74M-264.1%
Q1 FY2026Mar 31, 2026-$63.32M–
Q4 FY2025Dec 31, 2025-$17.67M-424.9%
Q3 FY2025Sep 30, 2025-$7.64M–
Q2 FY2025Jun 30, 2025$10.81M–
Q1 FY2025Mar 31, 2025-$6.53M–
Q4 FY2024Dec 31, 2024$5.44M–
Q3 FY2024Sep 30, 2024-$8.31M–
Q2 FY2024Jun 30, 2024-$29.17M–
Q1 FY2024Mar 31, 2024-$20.24M–
Q4 FY2023Dec 31, 2023-$25.77M–
Q3 FY2023Sep 30, 2023-$42.29M–
Q2 FY2023Jun 30, 2023-$46.72M–
Q1 FY2023Mar 31, 2023-$60.99M–
Q4 FY2022Dec 31, 2022-$308.76M–
Q3 FY2022Sep 30, 2022-$77.58M-337.0%
Q2 FY2022Jun 30, 2022-$85.74M–
Q1 FY2022Mar 31, 2022-$76.90M–
Q4 FY2021Dec 31, 2021-$40.19M–
Q3 FY2021Sep 30, 2021$32.73M–
Q2 FY2021Jun 30, 2021-$46.16M–
Q1 FY2021Mar 31, 2021-$191.78M–
Q4 FY2020Dec 31, 2020-$125.68M–
Q3 FY2020Sep 30, 2020-$56.62M–
Q2 FY2020Jun 30, 2020-$32.05M–
Q1 FY2020Mar 31, 2020-$26.99M–

More GeneDx figures

See a number that looks wrong?